Combining Antivirals and Immunomodulators to Fight COVID-19

The majority of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals remain paucisymptomatic, contrasting with a minority of infected individuals in danger of death. Here, we speculate that the robust disease resistance of most individuals is due to a swift production of...

Descripción completa

Detalles Bibliográficos
Autores principales: Feuillet, Vincent, Canard, Bruno, Trautmann, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664349/
https://www.ncbi.nlm.nih.gov/pubmed/33281063
http://dx.doi.org/10.1016/j.it.2020.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664349/
https://www.ncbi.nlm.nih.gov/pubmed/33281063
http://dx.doi.org/10.1016/j.it.2020.11.003

Ejemplares similares